Real-World Evidence For Control Of Chronic Migraine In Patients Meeting American Headache Society Criteria Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added To Onabotulinumtoxina

Objective: Combining onabotulinumtoxinA with CGRPmAbs can potentially be more effective than each therapy alone for preventing chronic migraine (CM). In the primary analysis cohort, records from 257 adults with CM receiving onabotulinumtoxinA with CGRPmAb showed that...